EP1524973A1 - Pharmazeutische zusammensetzung zur behandlung von chronischer myeloid leukämie - Google Patents

Pharmazeutische zusammensetzung zur behandlung von chronischer myeloid leukämie

Info

Publication number
EP1524973A1
EP1524973A1 EP03762826A EP03762826A EP1524973A1 EP 1524973 A1 EP1524973 A1 EP 1524973A1 EP 03762826 A EP03762826 A EP 03762826A EP 03762826 A EP03762826 A EP 03762826A EP 1524973 A1 EP1524973 A1 EP 1524973A1
Authority
EP
European Patent Office
Prior art keywords
composition
acid
cells
analogs
abl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03762826A
Other languages
English (en)
French (fr)
Inventor
Santu Indian Inst. of Chem. Bio. BANDYOPADHYAY
Bikash Chandra Indian Inst. of Chem. Bio. PAL
Samir Indian Inst. of Chem. Biology BHATTACHARYA
Kesheb Chandra Indian Inst. of Chem. Bio. ROY
Gautam Indian Inst. of Chem. Bio. BANDYOPADHYAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Council of Scientific and Industrial Research CSIR
Original Assignee
Council of Scientific and Industrial Research CSIR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/338,688 external-priority patent/US20030229140A1/en
Application filed by Council of Scientific and Industrial Research CSIR filed Critical Council of Scientific and Industrial Research CSIR
Publication of EP1524973A1 publication Critical patent/EP1524973A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • This invention relates to treatment of chronic myeloid leukemia (CML) by a composition comprising analogs of chlorogenic acid and/or its salts such as sodium chlorogenate (Na-Chl) or potassium or ammonium salts, which were prepared from Chlorogenic acid or its analogs.
  • CML chronic myeloid leukemia
  • AML Acute Myeloid Leukemia
  • CML Chronic Myeloid Leukemia
  • AML is characterized by an increase in the number of myeloid cells in the bone marrow and an arrest in their maturation.
  • AML is approximately 2.4 per 100,000 and it increases progressively with age, to a peak of 12.6 per 100,000 adults 65 years of age or older.
  • the CML is a malignant clonal disorder of hematopoietic stem cells.
  • the median age at presentation is 53 years, but it occurs at all age groups, including children.
  • the natural history of CML is progression from a benign chronic phase to a rapidly fatal blast crisis within three to five years or even earlier.
  • CD33 represents a specific and useful marker in the process of myeloid cell differentiation (2).
  • Recent reports suggest that engagement of CD33 by monoclonal antibody induced apoptosis leading to growth inhibition of proliferation of AML and CML cells in vitro (2,3).
  • Exploiting the myeloid specific expression of CD33 humanized anti-CD33 monoclonal antibody conjugated with anti- cancer drug has been tried in AML patients with significant success (4).
  • lymphoid leukemia is also subdivided in two groups: acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL).
  • ALL acute lymphocytic leukemia
  • CLL chronic lymphocytic leukemia
  • Lymphoid leukemia may affect both T and B cell lineages and are prevalent in children. With the extracts from Piper betel leaves anti- myeloid activity was claimed earlier (Patent filed no. PCT/TNOO/00118 dated December 12, 2000). Two compounds isolated from Piper betel extract also showed anti myeloid leukemic activity. One compound was 3-O-Coumaryl quinic acid (patent application no. US 60/384, 163 dated 31.05.2002). The other compound was Chlorogenic acid (patent application no. US 60/393750 dated 08.07.2002).
  • Chlorogenic acid (Chi) is known to have anti-allergic activity (5). Chi also inhibits hepatic and renal glucose-6-phosphatase systems (6). Chi is an inhibitor of epidermal lypoxygenase activity and TPA-induced ear inflammation (7). Chi also renders inhibitory effects on TPA-induced tumor promotion in mouse skin (7). Anti-HIN activity of Chi has also been reported (8).
  • Bcr-Abl constitutively active tyrosine kinase
  • CML chronic myelogenous leukemia
  • Highly potent small molecules are known to inhibit Bcr-Abl dependent cell growith 10 11 .
  • Piper betel inhibits Abl protein tyrosine kinase triggering apoptosis of Bcr-Abl expressing CML cell line K562. Elucidation of structure identifies this molecule as chlorogenic acid.
  • the main object of the invention is to provide a pharmaceutical composition comprising analogs of chlorogenic acid and/or its salts.
  • Another object of the present invention is to provide a pharmaceutical composition comprising analogs of chlorogenic acid and/or its salts for treating chronic myeloid leukemia.
  • Another object of the invention is to provide pharmaceutical composition
  • salts of chlorogenic acid and / or its salts such as sodium chlorogenate (NaChl) or potassium or ammonium salts, which were prepared from Chlorogenic acid or its analogs for the treatment of chronic myeloid leukemia.
  • Another object of the invention is to provide a new use of the compound sodium chlorogenate (NaChl) prepared from Chlorogenic acid (Chi) isolated from the Piper betel leaf extract or from any other sources for the treatment of chronic myeloid leukemia.
  • Another objective of the invention is to provide a new pharmaceutical composition comprising a carrier along with the compound sodium chlorogenate for the treatment of chronic myeloid leukemia.
  • Yet another objective of the invention is to provide a process for the preparation of sodium chlorogenate from Chlorogenic acid to treat CML.
  • Yet another objective of the invention is to provide a simplified method of preparation of NaChl from Chlorogenic acid which was isolated from all plant parts of Piper betel possessing biological activities relevant to the treatment of CML.
  • Yet another objective of the invention is to provide sodium salt of Chlorogenic acid a herbal product from leaves or any other plant parts of Piper betel for the treatment of CML.
  • the present provides a pharmaceutical composition for the treatment of chronic myeloid leukemia (CML) by a composition comprising analogs of chlorogenic acid and/or its salts such as sodium chlorogenate (Na-Chl) or potassium or ammonium salts, which were prepared from Chlorogenic acid or its analogs.
  • CML chronic myeloid leukemia
  • Na-Chl sodium chlorogenate
  • the present invention provides a pharmaceutical composition, which kills myeloid cancer cells leaving other normal cells unaffected.
  • Chronic myeloid leukemia is lethal, there is no drug directing towards the destruction of the leukemic cells, and these cells poorly respond to chemotherapy which is always non-specific thus adversely affecting normal cells.
  • the present invention provides a pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, said composition comprising an effective amount of analogs of chlorogenic acid and/or its salts along with pharmaceutically acceptable additives.
  • the said composition is also useful in treating diseases caused by over expression of Abl type of kinase
  • the analogs of chlorogenic is selected from a group consisting of neochlorogenic acid (5-O-caffeoyl quinic acid), cryptochlorogenic acid (4-O- Caffeoyl quinic acid), 3-O-(3'-methylcaffeoyl) quinic acid and 5 -O-(Caffeoyl-4' -methyl) quinic acid.
  • analogs of chlorogenic acid are obtained either from natural sources or synthetically prepared.
  • the salt of chlorogenic acid analog is selected from sodium, potassium and ammonium.
  • the additive is selected from a group consisting of nutrients such as proteins, carbohydrates, sugars, talc, magnesium stearate, cellulose, calcium carbonate, starch-gelatin paste and/or pharmaceutically acceptable carriers, excipient, diluents or solvents.
  • nutrients such as proteins, carbohydrates, sugars, talc, magnesium stearate, cellulose, calcium carbonate, starch-gelatin paste and/or pharmaceutically acceptable carriers, excipient, diluents or solvents.
  • the composition may administered through oral, intravenous, intramuscular or subcutaneous routes.
  • the said composition is administered at a dose level ranging between about 1 and 100 mg per kg body weight/day, preferably in the range of 1 to 25 mg/kg body weight.
  • the said composition may be administered for period ranging between at least four weeks and up to twelve weeks, and in case of relapse it can again can be administered to the subject without any toxicity.
  • the said composition inhibits the growth of leukemic cell types K562. and Molt-4.
  • the said composition inhibits the growth of leukemic cell types Molt-4.
  • composition, IC 50 value for in vitro activity against K562 cells of concentration of 10 /well is up to 27.0 nanomole/ml.
  • the IC50 values for chlorogenic acid and sodium chlorogenate on K562 cells is 13.5 and 27.0 ⁇ m/10 4 cells respectively (Fig 2C & 2D).
  • Another embodiment the acute toxicity of sodium chlorogenate in mouse model, wherein the compound is non-toxic up to a dose level of 2gm/kg body weight in oral route.
  • Fig. 1 Structure of sodium chlorogenate, one of the salts of chlorogenic acid..
  • Fig. 2 Purification of chlorogenic acid from Piper betel leaves and its effects on cell lines and Ph + " CML patients' PBMC in vitro.
  • the flow diagram of purification is shown.
  • the structure of peak 09 isolated from fraction E by HPLC was deduced as chlorogenic acid by spectroscopic methods (IR, NMR, 13 CNMR, FABMS).
  • Cell count assays were performed by plating cells in the presence of regular growth medium with or without indicated amount of extract (a), fraction (b), purified compound (c) and its sodium salt (d).
  • Example 2 The Chlorogenic acid is available in the market in the pure form. The Chlorogenic acid (1 gm) was hand shaken with sodium hydrogen carbonate (024 g in 5 ml of water) solution. The solution was lyophilised to pure sodium chlogogenate (1.12 gm) and was tested for biological activity. Sodium chlorogenate prepared from chlorogenic acid which was either isolated from Piper betel or obtain commercially have similar structure and activity.
  • Example 3 The Chlorogenic acid is available in the market in the pure form. The Chlorogenic acid (1 gm) was hand shaken with sodium hydrogen carbonate (024 g in 5 ml of water) solution. The solution was lyophilised to pure sodium chlogogenate (1.12 gm) and was tested for biological activity. Sodium chlorogenate prepared from chlorogenic acid which was either isolated from Piper betel or obtain commercially have similar structure and activity.
  • Example 3 The Chlorogenic acid is available in the market in the pure form. The Chlorogenic acid (1 gm) was hand shaken with sodium hydrogen
  • Bcr-Abl positive CML cell line K562
  • peripheral blood cells of CML patients Bcr-Abl-negative ALL cell line (Molt-4)
  • peripheral blood cells of CML patients Bcr-Abl-negative ALL cell line (Molt-4)
  • Cell count assays were performed by plating cells in the presence of regular growth medium with or without indicated amount of extract, fraction, purified compound and its sodium salt. Each day, viable cells were counted as assessed by exclusion of trypan blue.
  • NaChl has no effect on Bcr-Abl negative CML patients PBMC (Fig. 2e).
  • Phase contrast microscopy indicates that NaChl induces mo ⁇ hological changes (nuclear condensation) in K562 cells, sign of apoptosis (Fig. 2f).
  • the IC50 values for chlorogenic acid and sodium chlorogenate on K562 cells is 13.5 and 27.0 ⁇ m/10 4 cells respectively Fig 2C & 2D.
  • the compound is non-toxic upto the dose level of 2gm/kg body weight in oral route.
  • Results of examples 5 to 9 Treatment with NaChl did not induce apoptosis in Molt-4 cells, normal PBMC or PBMC of Bcr-Abl negative CML patients. In contrast, the same treatment cause an increase in apoptosis in Bcr-Abl positive K562 cells and PBMC of Bcr-Abl positive CML patients (Fig. 3 a). DNA cell cycle analysis also indicates that NaChl induces cell cycle arrest followed by breakdown of DNA in Bcr-Abl positive CML cell line K562 cells and PBMC of Bcr-Abl positive CML patients (Fig. 3b).
  • FIG. 3c Confocal microscopy indicating positive Annexin V staining in K562 cells but not in Molt-4 cells after treatment with NaChl is shown in Fig. 3c.
  • NaChl inhibits phosphorilation of Bcr-Abl protein tyrosine kinase without affecting the expression of Abl protein level. This is evident by flow cytometric detection of phospho-c- Abl status (Fig. 4a), and by immunoblot detection (Fig.
  • Fig.-4d shows that chlorogenic acid (Chi, Panel-B) can fit into the binding pocket of Abl kinase in the inactive conformation in a position similar to that of Gleevec (Panel-A) and in the active conformation (Panel-D) similar to that of PD173955 (Panel-C).
  • Empirical energies associated with the docking of the ligand into the binding pockets of the active and inactive conformations of the kinase are negative and comparable to those of other small molecule inhibitors e.g. Gleevec and PD 173955 indicating stable complex formation.
  • Chi Binding energies of Chi in charged and neutral forms are different and the magnitude of electrical interactions depends on the electrical state of the molecule unlike the neutral inhibitors.
  • Modeling studies indicate that Chi can bind to both the active and inactive conformations of the kinase like PD173955.
  • Chi forms a number of hydrogen bonds with the surrounding residues as found in the complex of Gleevec while keeping some of the hydrophobic interactions intact.
  • Chi forms higher number hydrogen bonds while maintaining similar number of hydrophobic contacts. It has been found that the aromatic hydroxyl groups of Chi forms a network of hydrogen bonds in the binding pocket suggesting the importance of these groups in the complex formation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP03762826A 2002-07-08 2003-01-10 Pharmazeutische zusammensetzung zur behandlung von chronischer myeloid leukämie Withdrawn EP1524973A1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
1997-03-05
US39375002P 2002-07-08 2002-07-08
US393750P 2002-07-08
US10/338,688 US20030229140A1 (en) 2002-05-31 2003-01-09 Herbal molecule as potential anti-leukemic drug
PCT/IB2003/000044 WO2004004708A1 (en) 2002-07-08 2003-01-10 A pharmaceutical composition useful for treating chronic myeloid leukemia

Publications (1)

Publication Number Publication Date
EP1524973A1 true EP1524973A1 (de) 2005-04-27

Family

ID=30118032

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03762826A Withdrawn EP1524973A1 (de) 2002-07-08 2003-01-10 Pharmazeutische zusammensetzung zur behandlung von chronischer myeloid leukämie

Country Status (4)

Country Link
EP (1) EP1524973A1 (de)
JP (1) JP2006519752A (de)
AU (1) AU2003201062A1 (de)
WO (1) WO2004004708A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2662126A1 (en) * 2006-09-01 2008-03-06 Piramal Life Sciences Limited Anti cancer use of caffeic acid and its derivatives
CA2673264A1 (en) * 2006-12-21 2008-07-03 Piramal Life Sciences Limited Herbal composition and process for its preparation
KR101145930B1 (ko) * 2007-06-11 2012-05-15 국립암센터 클로로겐산을 포함하는 트란스글루타미나제 억제제 및 그의제조방법
MX342465B (es) * 2010-06-01 2016-09-30 Biotheryx Inc * Metodos para tratar enfermedades hematologicas usando 6-ciclohexil-1-hidroxi-4-metil-2(1h)-piridona.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2904968B2 (ja) * 1991-07-25 1999-06-14 長谷川香料株式会社 色素の褪色防止剤
KR20020089440A (ko) * 2000-04-11 2002-11-29 다카라 바이오 가부시키가이샤 치료제
JP3859988B2 (ja) * 2000-07-12 2006-12-20 花王株式会社 高血圧症予防・改善・治療剤
GB2383753B (en) * 2000-12-04 2004-06-09 Council Scient Ind Res Antimonocytic activity of extracts of piper betel leaves

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2004004708A1 *

Also Published As

Publication number Publication date
AU2003201062A8 (en) 2004-01-23
WO2004004708A1 (en) 2004-01-15
WO2004004708A9 (en) 2006-05-04
AU2003201062A1 (en) 2004-01-23
JP2006519752A (ja) 2006-08-31

Similar Documents

Publication Publication Date Title
Kpemissi et al. Nephroprotective activity of Combretum micranthum G. Don in cisplatin induced nephrotoxicity in rats: In-vitro, in-vivo and in-silico experiments
Chen et al. Antitumor activity of Annona squamosa seed oil
WO2018215795A2 (en) Senolytic compounds
PL213644B1 (pl) Zastosowanie glikozydów mono- i diacyloglicerolu do wytwarzania leku do leczenia, lagodzenia lub profilaktyki stanów zapalnych
CN100515416C (zh) 能作为抗白血病药物的草药分子
Li et al. A011, a novel small-molecule ligand of σ2 receptor, potently suppresses breast cancer progression via endoplasmic reticulum stress and autophagy
KR20190098649A (ko) 칸나비디올 추출물을 함유하는 대장암 예방 또는 치료용 약학 조성물
EP0531413A1 (de) Antivirales arzneimittel enthaltend prostratin
US11957699B2 (en) Composition comprising punicalagin for inhibiting PAR2 activity
KR100711028B1 (ko) 향나무 추출물 또는 세드롤을 포함하는 비만 및 제2형당뇨병 예방 및 치료용 조성물
JPH1067656A (ja) 細胞接着抑制剤
WO2004004708A1 (en) A pharmaceutical composition useful for treating chronic myeloid leukemia
US20040006138A1 (en) Pharmaceutical composition useful for treating chronic myeloid leukemia
KR20050078743A (ko) 로즈마린산의 하이드록실페닐 유도체를 유효성분으로 하는항암용 약학 조성물
US8580847B2 (en) Antrocin containing pharmaceutical compositions for inhibiting cancer cells
US20070161704A1 (en) Pharmaceutical composition useful for treating chronic myeloid leukemia
CA2492278A1 (en) Pharmaceutical composition containing chlorogenic acid analogs for the treatment of chronic myeloid leukaemia
US20050282892A1 (en) Pharmaceutical composition useful for treating chronic myeloid leukemia
US20050175623A1 (en) Saponins as anticancer agent
KR100191901B1 (ko) 새로운 세스퀴테르펜 에스테르 화합물
Jun-Zhi et al. Activity tracking isolation of Gelsemium elegans alkaloids and evaluation of their antihuman gastric cancer activity in vivo
dos Santos et al. Antinociceptive and Anti-inflammatory Activities of the Methanolic Extract from the Stem Bark of Lophanthera lactescens
JP6627141B2 (ja) ベニバナボロギク抽出物を調製する方法、それにより調製された抽出物、及び抽出物の使用
Pettit et al. Biosynthetic products for anticancer drug design and treatment: the bryostatins
KR20050095287A (ko) 1, 2, 3, 4,6-펜타-오-갈로일-베타-디-글루코오스(피지지)의 암치료제및 예방제로서의 신규한 용도 및 오배자로부터 피지지를분리하는 방법

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050121

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

DAX Request for extension of the european patent (deleted)
RBV Designated contracting states (corrected)

Designated state(s): DE FR GB

17Q First examination report despatched

Effective date: 20061102

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100803